Virbac Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Virbac is de winst gegroeid met een gemiddeld jaarlijks percentage van 14%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 14%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 8.3% per jaar. Het rendement op eigen vermogen van Virbac is 14.2%, en het heeft een nettomarge van 10.5%.
Belangrijke informatie
14.0%
Groei van de winst
14.1%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 16.3% |
Inkomstengroei | 8.3% |
Rendement op eigen vermogen | 14.2% |
Nettomarge | 10.5% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 47% Undervalued
Oct 06Virbac SA Just Beat Revenue Estimates By 6.0%
Sep 18Unpleasant Surprises Could Be In Store For Virbac SA's (EPA:VIRP) Shares
Aug 31Why We Think Virbac SA's (EPA:VIRP) CEO Compensation Is Not Excessive At All
Jun 15Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Jun 10Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
May 21Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results
Mar 22Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?
Jan 18Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up
Dec 27Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet
Oct 19Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?
Sep 26Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching
Sep 05A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Jun 20Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?
May 31Is Virbac (EPA:VIRP) Using Too Much Debt?
Apr 09Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Feb 28Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 25Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?
Oct 14An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued
Aug 07These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely
Jun 26Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate
May 01We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease
Mar 26Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate
Jan 26Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock
Dec 28A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Oct 27Is Virbac (EPA:VIRP) Using Too Much Debt?
Oct 12Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today
Sep 26Is Virbac SA (EPA:VIRP) Trading At A 22% Discount?
Jul 15Is Now The Time To Put Virbac (EPA:VIRP) On Your Watchlist?
Jun 27Is Virbac (EPA:VIRP) A Risky Investment?
May 27Robust Earnings May Not Tell The Whole Story For Virbac (EPA:VIRP)
Mar 24Are Investors Undervaluing Virbac SA (EPA:VIRP) By 32%?
Mar 12Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching
Feb 22Is Virbac SA (EPA:VIRP) Popular Amongst Insiders?
Feb 03Virbac SA's (EPA:VIRP) Stock Is Going Strong: Is the Market Following Fundamentals?
Jan 05Does Virbac's (EPA:VIRP) Share Price Gain of 96% Match Its Business Performance?
Dec 18Opbrengsten en kosten
Hoe Virbac geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 1,339 | 141 | 605 | 0 |
31 Mar 24 | 1,293 | 131 | 589 | 0 |
31 Dec 23 | 1,247 | 121 | 573 | 0 |
30 Sep 23 | 1,229 | 120 | 570 | 0 |
30 Jun 23 | 1,210 | 119 | 568 | 0 |
31 Mar 23 | 1,213 | 121 | 563 | 0 |
31 Dec 22 | 1,216 | 122 | 557 | 0 |
30 Sep 22 | 1,184 | 120 | 535 | 0 |
30 Jun 22 | 1,151 | 119 | 513 | 0 |
31 Mar 22 | 1,107 | 116 | 500 | 0 |
31 Dec 21 | 1,064 | 113 | 487 | 0 |
30 Sep 21 | 1,025 | 137 | 473 | 0 |
30 Jun 21 | 985 | 161 | 459 | 0 |
31 Mar 21 | 960 | 148 | 449 | 0 |
31 Dec 20 | 934 | 136 | 439 | 0 |
30 Sep 20 | 944 | 104 | 444 | 0 |
30 Jun 20 | 953 | 72 | 448 | 0 |
31 Mar 20 | 946 | 62 | 451 | 0 |
31 Dec 19 | 938 | 52 | 454 | 0 |
30 Sep 19 | 921 | 43 | 449 | 0 |
30 Jun 19 | 903 | 34 | 445 | 0 |
31 Mar 19 | 886 | 27 | 446 | 0 |
31 Dec 18 | 869 | 20 | 446 | 0 |
30 Sep 18 | 862 | 8 | 442 | 0 |
30 Jun 18 | 854 | -4 | 438 | 0 |
31 Mar 18 | 858 | -3 | 440 | 0 |
31 Dec 17 | 862 | -3 | 442 | 0 |
30 Sep 17 | 871 | 16 | 444 | 0 |
30 Jun 17 | 879 | 35 | 446 | 0 |
31 Mar 17 | 876 | 35 | 449 | 0 |
31 Dec 16 | 872 | 35 | 452 | 0 |
30 Sep 16 | 861 | 30 | 459 | 0 |
30 Jun 16 | 850 | 26 | 466 | 0 |
31 Mar 16 | 851 | 18 | 463 | 0 |
31 Dec 15 | 853 | 9 | 460 | 0 |
30 Sep 15 | 846 | 21 | 441 | 0 |
30 Jun 15 | 839 | 32 | 421 | 0 |
31 Mar 15 | 806 | 48 | 398 | 0 |
31 Dec 14 | 773 | 64 | 375 | 0 |
30 Sep 14 | 752 | 60 | 366 | 0 |
30 Jun 14 | 730 | 56 | 357 | 0 |
31 Mar 14 | 733 | 58 | 356 | 0 |
31 Dec 13 | 736 | 61 | 355 | 0 |
Kwaliteitswinsten: VIRP heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (10.5%) VIRP } zijn hoger dan vorig jaar (9.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van VIRP is de afgelopen 5 jaar met 14% per jaar gegroeid.
Versnelling van de groei: De winstgroei van VIRP over het afgelopen jaar ( 18.5% ) overtreft het 5-jarig gemiddelde ( 14% per jaar).
Winst versus industrie: De winstgroei VIRP over het afgelopen jaar ( 18.5% ) overtrof de Pharmaceuticals -sector -19.9%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 14.2% ) van VIRP wordt als laag beschouwd.